310 related articles for article (PubMed ID: 33331178)
1. HIV-1 cure strategies: why CRISPR?
Atkins AJ; Allen AG; Dampier W; Haddad EK; Nonnemacher MR; Wigdahl B
Expert Opin Biol Ther; 2021 Jun; 21(6):781-793. PubMed ID: 33331178
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
4. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9: a tool to eradicate HIV-1.
Bhowmik R; Chaubey B
AIDS Res Ther; 2022 Dec; 19(1):58. PubMed ID: 36457057
[TBL] [Abstract][Full Text] [Related]
6. Elimination of infectious HIV DNA by CRISPR-Cas9.
Das AT; Binda CS; Berkhout B
Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
9. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.
Liu Y; Jeeninga RE; Klaver B; Berkhout B; Das AT
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960730
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic application of CRISPR/Cas9 technologies for HIV.
Saayman S; Ali SA; Morris KV; Weinberg MS
Expert Opin Biol Ther; 2015 Jun; 15(6):819-30. PubMed ID: 25865334
[TBL] [Abstract][Full Text] [Related]
11. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
12. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
[TBL] [Abstract][Full Text] [Related]
13. Systematic HIV-1 promoter targeting with CRISPR/dCas9-VPR reveals optimal region for activation of the latent provirus.
Klinnert S; Chemnitzer A; Rusert P; Metzner KJ
J Gen Virol; 2022 Jun; 103(6):. PubMed ID: 35671066
[TBL] [Abstract][Full Text] [Related]
14. Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery.
Klinnert S; Schenkel CD; Freitag PC; Günthard HF; Plückthun A; Metzner KJ
Gene Ther; 2024 Mar; 31(3-4):74-84. PubMed ID: 37558852
[TBL] [Abstract][Full Text] [Related]
15. Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy.
Herskovitz J; Hasan M; Patel M; Kevadiya BD; Gendelman HE
Methods Mol Biol; 2022; 2407():429-445. PubMed ID: 34985679
[TBL] [Abstract][Full Text] [Related]
16. Disruption or Excision of Provirus as an Approach to HIV Cure.
Jerome KR
AIDS Patient Care STDS; 2016 Dec; 30(12):551-555. PubMed ID: 27855263
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA.
Liu Y; Binda CS; Berkhout B; Das AT
J Virol; 2023 Dec; 97(12):e0133423. PubMed ID: 37982648
[TBL] [Abstract][Full Text] [Related]
18. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.
Wang G; Zhao N; Berkhout B; Das AT
Cell Rep; 2016 Dec; 17(11):2819-2826. PubMed ID: 27974196
[TBL] [Abstract][Full Text] [Related]
19. Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies.
Darcis G; Das AT; Berkhout B
Viruses; 2018 Mar; 10(4):. PubMed ID: 29596334
[TBL] [Abstract][Full Text] [Related]
20. Delivering CRISPR to the HIV-1 reservoirs.
Gurrola TE; Effah SN; Sariyer IK; Dampier W; Nonnemacher MR; Wigdahl B
Front Microbiol; 2024; 15():1393974. PubMed ID: 38812680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
